Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Sophie Dupuis‐Girod; Isabelle Ginon; Jean‐Christophe Saurin; Denis Marion; Elsa Guillot; Évelyne Decullier; Adeline Roux; Marie‐France Carette; Brigitte Gilbert‐Dussardier; Pierre‐Yves Hatron; Pascal Lacombe; B. Lorcerie; Sophie Rivière; R. Corre; Sophie Giraud; Sabine Bailly; Gilles Paintaud; David Ternant; Pierre‐Jean Valette; Henri Plauchu; Fréderic Faure

doi:10.1001/jama.2012.250

Key Points

To evaluate the clinical efficacy and safety of bevacizumab in treating patients with hereditary hemorrhagic telangiectasia who suffer from severe hepatic vascular malformations and elevated cardiac output.
Interventional clinical trial registered under clinicaltrials.gov identifier NCT00843440.
Evaluated the administration of bevacizumab in individuals diagnosed with hereditary hemorrhagic telangiectasia with documented hepatic vascular malformations.
Clinical outcomes assess the antiangiogenic effect of bevacizumab on reducing hepatic vascular shunting and hyperdynamic cardiac states.
Safety and hemodynamic efficacy endpoints are documented in trial registry NCT00843440.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical trial investigates bevacizumab for hereditary hemorrhagic telangiectasia with hepatic malformations, highlighting targeted antiangiogenic therapy to manage high cardiac output.

Abstract

clinicaltrials.gov Identifier: NCT00843440.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dupuis‐Girod et al. (2012) studied this question.

synapsesocial.com/papers/69dbe69bd60f0b8828835a5d https://doi.org/10.1001/jama.2012.250

View at Publisher

Ask AI

Bookmark

Share

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading